NasdaqGM - Delayed Quote USD

Lumos Pharma, Inc. (LUMO)

Compare
4.4000 +0.0500 (+1.15%)
At close: 4:00 PM EDT
Loading Chart for LUMO
DELL
  • Previous Close 4.3500
  • Open 4.3400
  • Bid --
  • Ask --
  • Day's Range 4.3100 - 4.4600
  • 52 Week Range 1.3700 - 4.5800
  • Volume 135,231
  • Avg. Volume 96,329
  • Market Cap (intraday) 35.828M
  • Beta (5Y Monthly) 0.36
  • PE Ratio (TTM) --
  • EPS (TTM) -4.4200
  • Earnings Date Nov 5, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 9.69

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

lumos-pharma.com

33

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LUMO

View More

Performance Overview: LUMO

Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LUMO
38.36%
S&P 500
21.77%

1-Year Return

LUMO
10.00%
S&P 500
36.74%

3-Year Return

LUMO
51.33%
S&P 500
27.79%

5-Year Return

LUMO
175.00%
S&P 500
92.94%

Compare To: LUMO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LUMO

View More

Valuation Measures

Annual
As of 10/24/2024
  • Market Cap

    35.34M

  • Enterprise Value

    18.99M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    23.70

  • Price/Book (mrq)

    3.44

  • Enterprise Value/Revenue

    12.78

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -60.50%

  • Return on Equity (ttm)

    -132.56%

  • Revenue (ttm)

    1.49M

  • Net Income Avi to Common (ttm)

    -35.75M

  • Diluted EPS (ttm)

    -4.4200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.8M

  • Total Debt/Equity (mrq)

    4.37%

  • Levered Free Cash Flow (ttm)

    -22.13M

Research Analysis: LUMO

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 488k
Earnings -7.55M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

4.25
9.69 Average
4.4000 Current
26.00 High
 

Company Insights: LUMO

People Also Watch